ClinicalTrials.gg
CompletedNCT03734302Updated Nov 1, 2023

The Pharmacokinetics, and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects

A Phase 1 interventional study of Brexpiprazole in Healthy, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-01.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This study is a single-center, open-label study evaluating the pharmacokinetics and safety of multiple dose oral administration of Brexpiprazole (1 mg) tablets in Chinese healthy subject.10 healthy adult subjects will be enrolled in this study. A single dose (Brexpiprazole 1 mg) group is set and the test drug will be administered for 14 consecutive days.

Read the detailed description

10 healthy adult subjects will be enrolled in this study. A single dose (Brexpiprazole 1 mg) group is set and the test drug will be administered for 14 consecutive days.

After receiving the informed consent form the subject themselves, the investigators start the screening 14 days to 1 days prior to taking the study drug (D-14 to D-1).

One day before first dosing (D-1), subjects are hospitalized. On the next day (D1), after completed the hospitalization inspection, eligible subjects will be selected to start with the first dose, and from day 1 to day 14 (D1 to D14), continue once daily dosing and complete the corresponding inspection, observation and blood sampling. They continue hospitalization and are discharged on day 17 (D17) after completing the relevant examinations. On days 19, 21, 23,25 (D19, D21,D23 and D25), blood samples are collected and safety evaluation is performed.

Telephone follow-up is performed on day 44 (D44, 30 days after the last dose of the drug).

Subjects who early terminated the test after taking the study drug should be tested at the end of the study (D25/ET) as far as possible.

Blood samples for pharmacokinetic evaluation are collected before daily dosing; D1 (before dosing, and 1, 2, 3, 4, 5, 6, 8, 12 hours after dosing), D2 (before dosing and 24 hours after first dosing), D10 (before dosing), D11 (before dosing), D12 (before dosing), D13 (before dosing), D14 (before dosing, and 1, 2, 3, 4, 5, 6, 8, 12 hours after dosing), D15 (24 hours after last dosing), D16 (48 hours after last dosing), D17 (72 hours after last dosing), D18 (96 hours after last dosing), D19 (120 hours after last dosing), D21 (168 hours after last dosing),D23 (216 hours after last dosing), D25 (264 hours after last dosing). 31 Blood samples collecting points in total.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Otsuka Beijing Research Institute is the lead sponsor of 36 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Sign the form
    1. At the age of 18\~45 years old (including upper and lower limits).
    1. Body weight of not less than 45 kg, 19 \~ 25kg/m2 range (including the upper and lower limits) [ body mass index (BMI) = body weight (kg) / height2 (m2)].

Exclusion criteria

Exclusion Criteria:

    1. Participated in any drug test within 12 weeks prior to enrollment.
    1. Drug abuse in the past 2 years or a history of substance abuse.
    1. Drinking alcohol more than 2 unit per day (1 unit= 360 ml beer , or 45 ml 4.0% alcohol, or 150 ml liquor, or 50 ml wine ) 6 months before the screening, or subjects can not stop drinking during the hospitalization.
    1. Drug abuse urine test at screening is positive.

Other protocol-defined inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Multiple dose oral administration

    1mg Once Daily (QD) , oral administration,14 consecutive days

    Drug: Brexpiprazole

Interventions

  • Brexpiprazole , mutiple dose /oral/empty stomach

    Also known as: Brex

06

What researchers measure

Primary outcomes

  1. Steady-state peak time (Tss_max)

    Assessment of the steady-state peak time of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  2. Steady-state valley concentration(Css_min)

    Assessment of the steady-state valley concentration of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  3. Steady-state peak concentration (Css_max)

    Assessment of the steady-state peak concentration of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  4. Average steady-state plasma concentration (Css_av)

    Assessment of the average steady-state plasma concentration (Css_av) of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  5. Half-life (t1/2, z)

    Assessment of the Half-life of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  6. Steady-state clearance (CLss/F)

    Assessment of the steady-state clearance of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  7. Area under steady state plasma concentration-time curve (AUC)ss

    Assessment of the area under steady state plasma concentration-time curve of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  8. Fluctuation index (DF)

    Assessment of the fluctuation index of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

  9. Cumulative coefficient (RAUC, Rcmax)

    Assessment of the cumulative coefficient of Brexpiprazole

    Time frame: Day1, Day2, Day10, Day11, Day12, Day13, Day14, Day15, Day16, Dv17, Day18, Day19, Dv21,Day23, Day25

Secondary outcomes

  1. The peak concentration (Cmax) after the first administration

    The peak concentration (Cmax) of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.

    Time frame: Day1, Day2

  2. The peak time (Tmax) after the first administration

    The peak-time of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.

    Time frame: Day1, Day2

  3. Area under the plasma concentration-time curve (AUC0-24h)

    The area under the plasma concentration-time curve of Brexipiprazole and the metabolite DM-3411 on the first day after administration are calculated.

    Time frame: Day1, Day2

  4. Valley concentration points

    Descriptive statistics about the valley concentration points before taking the study drug on days 10, 11, 12, 13 and 14

    Time frame: Day10, Day11, Day12, Day13, Day14

07

Study locations

1 site
  • Beijing Anding Hospital of Capital Medical University
    Beijing, Beijing 100088, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2020, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2018
First posted
Nov 7, 2018
StartActual
Apr 24, 2019
Primary completionActual
Jun 10, 2020
CompletionActual
Jun 10, 2020
Last update
Nov 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03734302
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Apr 24, 2019
Primary completion
Jun 10, 2020
Completion
Jun 10, 2020
Last update
Nov 1, 2023

Study contacts

Tao Jiang, Master
principal investigator · Beijing Anding Hospital of Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion